PRO 140: Phase III started

CytoDyn began a modified, double-blind, placebo-controlled, U.S. Phase III trial to evaluate 350 mg subcutaneous PRO 140 once weekly plus standard of care antiretroviral therapy (ART) in treatment-experienced HIV-infected patients who are failing their ART therapy. The modified protocol reduced enrollment to 150 patients from 300 patients and relaxed enrollment criteria allowing HIV-infected patients to enter the study before confirmation of the R5 strain -- the HIV subtype targeted by PRO 140. ...